About 30 results found for searched term "S-Me-DM4" (0.221 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M59005 | S-Me-DM4 | Metabolite/Endogenous Metabolite |
| Maytansinoid DM4 Impurity 3 | ||
| S-Me-DM4 is a metabolite of DM4 S-methylated by intracellular enzyme. | ||
| M45166 | LWY713 | PROTAC |
| LWY713 is a PROTAC molecule targeting FLT3 with acetyl group as linker, which can selectively induce FLT3 degradation in CRBN and proteasome-dependent manner, with a DC50 of 0.64 nM and a Dmax of 94.8%, and possesses antitumor activity. | ||
| M2731 | GSK-J4 hydrochloride | Histone demethylase |
| GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC50 of 9 μM. GSK J4 hydrochloride is a cell permeable procompound of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM and inactive against a panel of demethylases of the JMJ family. | ||
| M3650 | Meclofenoxate hydrochloride | AChR/AChE |
| Meclofenoxate hydrochloride is an ester of dimethylethanolamine (DMAE) and 4-chlorophenoxyacetic acid (pCPA). | ||
| M6259 | CP2 | Histone demethylase |
| CP2 is a cyclic peptide that inhibits the JmjC histone demethylases KDM4 with IC50 values of 42 nM and 29 nM for KDM4A and KDM4C, respectively. | ||
| M8299 | Methylstat | Others |
| Methylstat is an inhibitor of the Jumonji C domain-containing histone trimethyl demethylases (JHDMs). Methylstat inhibits the activity of JMJD2C (IC50 = 4.3 μM), with similar potency against JMJD2E and JMJD3. | ||
| M8620 | AS8351 | Others |
| AS8351 is an iron chelator that has been found to inhibit of histone demethylase KDM5B (JARID1B), a histone H3K4 demethylase involved in regulation of cell proliferation and stem cell self-renewal and differentiation. | ||
| M8769 | Tasimelteon | Melatonin Receptor |
| BMS-214778; VEC-162 | ||
| Tasimelteon (BMS-214778) is a Dual Melatonin Receptor Agonist (DMRA) recently approved (Hetlioz) for the treatment of Non-24-hour sleep–wake disorder, a disorder primarily found in the totally blind, where a lack of normal synchronization between the 24-hour light–dark cycle and the endogenous circadian rhythm causes it to drift out of alignment with conventional sleep–wake schedules. | ||
| M10374 | AMG 232 | Mdm2 |
| Navtemadlin ; KRT-232 | ||
| AMG 232 is an extremely potent MDM2 inhibitor (SPR KD = 0.045 nM, SJSA-1 EdU IC50 = 9.1 nM), with remarkable pharmacokinetic properties and in vivo antitumor activity in the SJSA-1 osteosarcoma xenograft model (ED50 = 9.1 mg/kg). *The compound is unstable in solutions, freshly prepared is recommended | ||
| M10860 | MRK-740 | Histone Methyltransferase |
| MRK-740 is a potent, selective, substrate-competitive PRDM9 histone methyltransferase inhibitor,IC50 80 nM. MRK-740 is more selective to PRDM9 than other histone methyltransferases and other non-epigenetic targets. MRK-740 Reduces PRDM9-Dependent H3K4 Trimethylation (IC50 0.8 μM). | ||
| M13834 | KDM4D-IN-1 | Histone demethylase |
| KDM4D-IN-1 is a new histone lysine demethylase 4D (KDM4D) inhibitor with an IC50 value of 0.41±0.03 μM. | ||
| M13835 | KDM5A-IN-1 | Histone demethylase |
| KDM5A-IN-1 is a potent, orally bioavailable pan-histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 45 nM, 56 nM and 55 nM for KDM5A, KDM5B and KDM5C, respectively, and with an EC50 value of 960 nM for PC9 H3K4Me3. | ||
| M14688 | DMT1 blocker 1 | Others |
| DMT1 blocker 1 is a blocker of divalent metal transporter 1 (DMT1) with an IC50 of 0.64 μM, is expected to block iron uptake by enterocytes in vivo. | ||
| M28481 | KDM2/7-IN-1 | Histone demethylase |
| KDM2/7-IN-1 (TC-E 5002) is a selective histone demethylase KDM2/7 subfamily inhibitor (IC50 values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 μM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively). KDM2/7-IN-1 inhibits growth of HeLa and KYSE-150 cancer cells in vitro. | ||
| M28622 | RO6889678 | Anti-infection |
| RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes. RO6889678 is metabolized by a combination of CYP3A4-mediated oxidation and UDP-glucuronosyltransferase UGT1A3- and UGT1A1-mediated direct glucuronidation. | ||
| M28643 | KDM5-C49 | Histone demethylase |
| KDOAM-20 | ||
| KDM5-C49 (KDOAM-20) is a potent and selective inhibitor of KDM5 demethylases, with IC50s of 40 nM, 160 nM, and 100 nM for KDM5A, KDM5B, and KDM5C enzymes, respectively. KDM5-C49 can be used for the research of cancer. | ||
| M28644 | KDM5-C70 | Histone demethylase |
| KDM5-C70 is an ethyl ester derivative of KDM5-C49 and a potent, cell-permeable and pan-KDM5 histone demethylase inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels. | ||
| M29391 | KDOAM-25 | Histone demethylase |
| KDOAM-25 is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells. | ||
| M29604 | JQKD82 | Histone demethylase |
| JADA82; PCK82 | ||
| JQKD82 (JADA82) is a cell-permeable and selective KDM5 inhibitor. JQKD82 increases H3K4me3 and can be used for the research of multiple myeloma. | ||
| M29650 | KDOAM-25 citrate | Histone demethylase |
| KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 citrate increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells. | ||
| M29850 | IMB-XH1 | Bcl-2 |
| IMB-XH1 is an inhibitor of myeloid cell factor 1 (Mcl-1). IMB-XH1 is a non-competitive Delhi metallo-β-lactamase (NDM-1) inhibitor. The IC50s of IMB-XH1 against metallo-β-lactamases NDM-1, IMP-4, ImiS and L1 are 0.4637 μM, 3.980 μM, 0.2287 μM and 1.158 μM, respectively. | ||
| M30520 | YUKA1 | Histone demethylase |
| YUKA1 is a potent and cell permeable Lysine demethylase 5A (KDM5A) inhibitor, with an IC50 of 2.66 μM, less active on KDM5C (IC50, 7.12 μM), and is inactive on KDM5B, KDM6A or KDM6B. YUKA1 increases H3K4me3 levels in human cells with anti-cancer activity. | ||
| M31014 | JQKD82 trihydrochloride | Histone demethylase |
| JADA82 trihydrochloride; PCK82 trihydrochloride | ||
| JQKD82 (JADA82) trihydrochloride is a cell-permeable and selective KDM5 inhibitor. JQKD82 trihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma. | ||
| M31015 | KDM5-C49 hydrochloride | Histone demethylase |
| KDOAM-20 hydrochloride | ||
| KDM5-C49 (KDOAM-20) hydrochloride is a potent and selective inhibitor of KDM5 demethylases, with IC50s of 40 nM, 160 nM, and 100 nM for KDM5A, KDM5B, and KDM5C enzymes, respectively. KDM5-C49 hydrochloride can be used for the research of cancer. | ||
| M31018 | KDOAM-25 trihydrochloride | Histone demethylase |
| KDOAM-25 trihydrochloride is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 trihydrochloride increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells. | ||
| M40544 | Mirvetuximab soravtansine | ADC Linker |
| Mirvetuximab soravtansine is an antibody-drug concatenation (ADC) containing a folate receptor alpha (frα)-conjugated antibody, a cleavable junction, and the medenosine alkaloid DM4, a potent microtubulin-targeting agent, that can be used in studies related to platinum-resistant epithelial ovarian cancer (EOC). | ||
| M42882 | KDM5B-IN-4 | Others |
| KDM5B-IN-4 is a lysine demethylase 5B (KDM5B) inhibitor with an IC50 of 0.025 μM KDM5B-IN-4 increases substrate H3K4me1/2/3 level by inhibiting KDM5B in PC-3 cells. | ||
| M54719 | O4I3 | Cell Culture |
| O4I3 is a potent and selective inhibitor of the KDM5A (JARID1A) isoform of H3K4 demethylase, with an IC50 value of 0.15 nM.O4I3 effectively induces OCT4 expression and enhances OSKM-induced pluripotent stem cell reprogramming efficiency (50 nM) of human primary fibroblasts by preventing KDM5A from interfering with the enrichment of H3K4Me3 on the OCT4 promoter. iPSC) reprogramming efficiency (50 nM). | ||
| M56052 | Zavondemstat | Histone demethylase |
| Zavondemstat (QC8222; TACH 101) is an inhibitor of histone lysine demethylase 4D (KDM4D) with antineoplastic activity. | ||
| M56051 | Zavondemstat L-lysine | Histone demethylase |
| Zavondemstat (QC8222; TACH 101) (L-lysine) is an inhibitor of histone lysine demethylase 4D (KDM4D) with antineoplastic activity. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
